

LETTER TO THE EDITOR

FLUMAZENIL IS A BENZODIAZEPINE RECEPTOR ANTAGONIST

Sir,

(Received on March 25, 2001)

This refers to the review article entitled 'Antiepileptic Drug Therapy in the Twenty First Century' by Y. K. Gupta and Jatinder Malhotra (1). In this article, the authors

have classified flumazenil as a benzodiazepine (BDZ) agonist (see Table IV). Flumazenil is in fact a specific BDZ antagonist with modest anticonvulsant activity (2-4).

NARESH KHANNA

*Department of Pharmacology,
UCMS, Delhi - 110 095*

REFERENCES

1. Gupta YK, Malhotra J. Antiepileptic drug therapy in the twenty first century. *Indian J Physiol Pharmacol* 2000; 44: 8-23.
2. Schmidt-Mutter C, Pain L, Sandner G, et al. The anxiolytic effect of gamma-hydroxybutyrate in the elevated plus maze is reversed by the benzodiazepine receptor antagonist, flumazenil. *Eur J Pharmacol* 1998; 342: 21-27.
3. Khan GM, Smolders I, Ebinger G, Michotte Y.

Flumazenil prevents diazepam-elicited anticonvulsant action and concomitant attenuation of glutamate outflow. *Eur J Pharmacol* 2000; 139-144.

4. Przegalinski E, Tatarezynska E, Chojnacka-Wojcik E. The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC rats. *Neuropharmacology* 2000; 39: 1858-1864.

From Editor's Desk

We are thankful to Dr. Naresh Khanna for pointing out the error in the review article on 'Antiepileptic Drug Therapy in the Twenty First Century' published in *Ind J Physiol Pharmacol* 2000; 44: 8-23.